Abiomed

Abiomed is a publicly-traded medical devices company that develops and manufactures external and implantable circulatory support devices. The company is headquartered in Danvers, Massachusetts and has three additional offices, two in Germany in the cities of Berlin and Aachen, and another in Tokyo, Japan. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer, Dr. Chuck Simonton as Chief Medical Officer and Dr. David M. Weber as Chief Operating Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients".[2] As of 2019, the company had secured five FDA approvals and 715 patents with 622 pending.[3] For fiscal year 2019, Abiomed reported $769.4 million in revenue and reported diluted earnings per share was $5.61 for the year.[4]

Abiomed, Inc.
TypePublic
IndustryMedical Devices
Founded1981
HeadquartersDanvers, Massachusetts, U.S.
Key people
Michael R. Minogue, CEO
Thorston Siess, CTO
Chuck Simonton, CMO
Dr. David M. Weber, COO
Andrew Greenfield, CCO
ProductsCardiovascular medical implant devices
Revenue US$769.43 million (2019)
US$224.81 million (2019)
US$259.02 million (2019)
Total assets US$1,054.3 million (2019)
Total equity US$936.89 million (2019)
Number of employees
1,371 (March 31, 2019)
Websiteabiomed.com
Footnotes / references
[1]

History

Abiomed was founded in Danvers, Massachusetts by David M. Lederman in 1981 as Applied Biomedical Corporation.[5] That year, the company commenced the development of an artificial heart.[6] Funded by federal research grants,[7] Lederman partnered with The Texas Heart Institute to develop the AbioCor, a grapefruit-sized electromagnetic device with an internal battery that completely replaces the heart without wires or tubes passing through the skin.[5] In July 2001, AbioCor became the first artificial heart successfully implanted in a patient, where it pumped more than 20 million times.[8] Fourteen of the AbioCor devices were implanted, during clinical trials from 2001 to 2004, with the longest-living recipient surviving 512 days.[5] The AbioCor won FDA approval in 2006 for patients who are near death and do not qualify for a heart transplant.[6]

In 2004, Michael R. Minogue became president and CEO of Abiomed.[9] In 2005, Abiomed purchased ventricular assist device company Impella CardioSystems AG of Aachen, Germany,[10] maker of the Impella heart pump, developed by Thorsten Siess,[11] who is now the Chief Technology Officer at Abiomed.[12] After Abiomed acquired Impella the company's focus shifted from heart replacement to heart recovery.[13]

In July 2014, Abiomed acquired German heart pump maker ECP in a deal worth up to $30 million. The deal included a nearly $2.8 million buyout of AIS GmbH Aachen Innovative Solutions, which owns some of the patents licensed to ECP.[14]

In May 2018, Abiomed was added to the S&P 500 index.[15] During the S&P's rise from 2000 to 3000, Abiomed was the index's top performing stock.[16]

In 2018, Abiomed built a $17 million Innovation Center to facilitate research and product development. The 29,800-square-foot facility features laboratories for blood, optical, software, mechanical and electrical research, plus a production line.[17]

In 2019, Barron's ranked Abiomed the 4th best stock of the 2010s, with total return of 1,983%.[18] while Fortune ranked Abiomed 19th on the magazine's list of 100 fastest-growing companies.[19]

In April 2020, Abiomed acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system.[20]

Impella products

Impella is the world's smallest heart pump.[15] It sits in the heart, spinning up to 50,000 revolutions per minute, sending blood throughout the body, allowing the heart to recover. It is inserted through a minimally invasive procedure and guided through an artery to the heart.[13] In 2007, the Impella 2.5 heart pump was among 35 healthcare products to receive a 2007 Medical Design Excellence Award.[21] As of August 2020, the Impella heart pump products include the Impella 2.5, Impella 5.0/LD, Impella CP with SmartAssist, Impella 5.5 with SmartAssist, Impella RP and Impella Connect.[22]

Since 2005 when Abiomed acquired the Impella technology,[23] the heart devices have received a series of FDA approvals.[24] Notably, in 2015, Abiomed received FDA approval to use the Impella 2.5 heart pump during elective and urgent high-risk percutaneous coronary intervention procedures. In 2016, the Impella RP system became the first percutaneous single-access heart pump designed for right-heart support to receive FDA approval.[25] The FDA approval was based on the PROTECT II randomized controlled trial, which found high-risk percutaneous coronary intervention (PCI) patients who underwent PCI with Impella had fewer major adverse events at 90 days, compared to patients who underwent PCI with the intra-aortic balloon pump (IABP).[26]

A 2020 study of 21,848 non-emergent, high-risk patients who underwent PCI with percutaneous ventricular assist devices (PVADs), including Impella, demonstrated the PVAD patients had a lower rate of mortality and complications than patients who underwent PCI with IABPs. As of 2020, the Impella heart pump is the most studied mechanical circulatory support device in the history of the FDA with more than 14 years of studies, clinical data on more than 140,000 patients, and more than 650 peer-reviewed publications.[27]

Leadership

Michael R. Minogue, Chairman, CEO & President, took over as chief executive in 2004 when Abiomed's founder, David Lederman, stepped down.[6] Minogue is a former Army Ranger and Operation Desert Storm veteran with an engineering degree from West Point and an MBA from the University of Chicago. Prior to Abiomed, Minogue spent eleven years with General Electric Healthcare.[28] Minogue helped found the Medical Technology Veterans Program (MVP), a career training and mentorship initiative designed to help veterans entering the civilian workforce transition into jobs in the medical device and life sciences industries,[29] and also serves on the boards of directors for the medical device industry association AdvaMed,[30] Insulet Corporation,[31] and the Medical Device Innovation Consortium.[32]

See also

References
  1. "US SEC: 2019 Form 10-K ABIOMED, Inc". U.S. Securities and Exchange Commission. May 23, 2019. Retrieved August 19, 2019.
  2. https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=247589
  3. "Highest Court in Germany Affirms Strength of Abiomed's Patents". Bloomberg. 23 September 2019. Retrieved 2 August 2020.
  4. "Abiomed FY 2019 Annual Report," Abiomed.com, retrieved July 29, 2010.
  5. Hevesi, Dennis (2012-08-28). "David Lederman, Pioneer of Artificial Heart, Dies at 68". The New York Times. ISSN 0362-4331. Retrieved 2020-08-03.
  6. Altman, Lawrence K. (2006-09-06). "Implantable Heart Device Receives F.D.A. Approval". The New York Times. ISSN 0362-4331. Retrieved 2016-07-19.
  7. Regalado, Antonio. "CPR for the Artificial Heart". Retrieved 2016-07-19.
  8. Altman, Lawrence K. (2001-12-01). "Man With Artificial Heart Dies 5 Months After Implant". The New York Times. ISSN 0362-4331. Retrieved 2016-07-19.
  9. "New Abiomed chief Minogue looks to pump up sales - Boston Business Journal". Boston Business Journal. Retrieved 2016-07-19.
  10. "Abiomed to pay $45M to buy Impella CardioSystems - Boston Business Journal". Boston Business Journal. Retrieved 2016-07-19.
  11. Burke, Alan. "How to mend a broken heart, and make millions". Retrieved 2016-07-19.
  12. "ABIOMED, Inc. - Management". investors.abiomed.com. Archived from the original on 2016-09-11. Retrieved 2016-07-19.
  13. Faulkner, Sarah (10 October 2017). "How Abiomed became a major medical device company". Medical Design & Outsourcing. Retrieved 5 August 2020.
  14. "Abiomed acquires German heart pump maker ECP". MassDevice. Retrieved 2020-03-31.
  15. "Abiomed (ABMD) to Replace Wyndham in the S&P 500 Benchmark," Nasdaq.com, retrieved August 9, 2020.
  16. Osipovich, Alexander (10 July 2019). "Videogames and Two-Day Delivery Powered the S&P's Rise to 3000". The Wall Street Journal. Retrieved 15 August 2020.
  17. "Abiomed Celebrates Opening of New Innovation Center in Danvers". Northshore Magazine. 6 August 2018. Retrieved 13 August 2020.
  18. Hough, Jack. "10 Stocks That Had Better Decades Than Amazon and Google". www.barrons.com. Retrieved 2020-07-27.
  19. "100 Fastest-Growing Companies Rank 19". Fortune. Retrieved 8 August 2020.
  20. Rachal, Maria (2020-04-30). "Abiomed buys artificial lung device for use with Impella, potential COVID 19 patients". MedTechDive. Retrieved 2020-05-29.
  21. "Abiomed Impella 2.5 Recognized for Innovative Design". Retrieved 2016-07-19.
  22. "Impella". Abiomed. Abiomed.com. Retrieved 8 August 2020.
  23. Faulkner, Sarah (October 10, 2017). "How Abiomed became a major medical device company". Medical Design & Outsourcing.
  24. "A mobile lab about heart pumps stops in Lincoln". Retrieved 2016-07-19.
  25. Alexandra Pecci, "Impella Heart Pump by Abiomed," Northshore Magazine, February 25, 2016.
  26. Brooks, Megan (21 September 2017). "FDA Okays Abiomed's Impella Heart Pump for Right Heart Failure". MedScape. Retrieved 22 August 2020.
  27. "High-Risk PCI Patients who Receive PVADs (Impella) have Lower Risk of Death and Complications: Study". Cardiology 2.0. 4 March 2020. Retrieved 22 August 2020.
  28. Weisman, Robert (21 October 2016). "Five things you should know about Mike Minogue". The Boston Globe. Retrieved 16 August 2020.
  29. "About - MVPvets". Retrieved 2016-07-19.
  30. "Board of Directors". AdvaMed. Retrieved 20 August 2020.
  31. "Board of Directors". Insulet Corporation. Retrieved 20 August 2020.
  32. "Board of Directors". MDIC. Retrieved 20 August 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.